The expression of GLP-1R in islets is downregulated in hyperglycemia and its expression is restored by correction of the hyperglycemia by treatment with phlorizin and luseogliflozin [49,82], and therefore it is reasonable to expect that therapy with a combination of an SGLT2i and an incretin-related agent would have a positive effect on β-cell function. The gene discussed is GLP1R; the disease is Hyperglycemia.